Attruby (acoramidis) slows disease progression and significantly reduces death and cardiovascular-related hospitalizations in adults with hereditary or wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) across several subgroups, according to new analyses of data from a clinical trial and its extension.
Benefits were detected as early as three months and were sustained for up to 3.5 years, without new safety concerns.